Cargando…

Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma

This indirect comparison of dupilumab, mepolizumab and omalizumab for patients with severe type 2 asthma fulfilling start-up criteria for more than one drug shows no significant efficacy differences https://bit.ly/3pK9Nf9

Detalles Bibliográficos
Autores principales:	Prætorius, Katrine, Henriksen, Daniel P., Schmid, Johannes M., Printzlau, Pernille, Pedersen, Lars, Madsen, Hanne, Andersson, Ehm A., Madsen, Louise Klokker, Chawes, Bo L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405862/ https://www.ncbi.nlm.nih.gov/pubmed/34476242 http://dx.doi.org/10.1183/23120541.00306-2021

Ejemplares similares

Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis
por: Henriksen, Daniel P., et al.
Publicado: (2018)

Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma
por: Henriksen, Daniel P., et al.
Publicado: (2020)

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab
por: Li, Lisha, et al.
Publicado: (2021)

Appropriate selection for omalizumab treatment in patients with severe asthma?
por: Nygaard, Leo, et al.
Publicado: (2017)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
por: Menzella, Francesco, et al.
Publicado: (2017)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
por: Giovannini, Mattia, et al.
Publicado: (2019)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
por: Liu, Mark C., et al.
Publicado: (2021)

The phenotypic heterogeneity of obese and nonobese patients with severe asthma and comparison of omalizumab–mepolizumab treatment efficiency in these patients
por: Özden, Şeyma, et al.
Publicado: (2023)

A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
por: Davison, John, et al.
Publicado: (2021)

Mepolizumab/omalizumab/triamcinolone: Lack of efficacy and rebound effect: case report
Publicado: (2022)

Successful Treatment of Mepolizumab- and Prednisolone-resistant Allergic Bronchopulmonary Aspergillosis with Dupilumab
por: Mikura, Sunao, et al.
Publicado: (2021)

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2020)

Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic “Overlap” severe asthma: Biological agent preference in atopic-eosinophilic severe asthma
por: Tepetam, Fatma Merve, et al.
Publicado: (2023)

Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis
por: Charles, David, et al.
Publicado: (2022)

High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab
por: Madsen, Hanne, et al.
Publicado: (2021)

Comparison of different medical treatment options for CRSwNP: doxycycline, methylprednisolone, mepolizumab and omalizumab
por: De Schryver, Els, et al.
Publicado: (2015)

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
por: Seyed Jafari, S. Morteza, et al.
Publicado: (2021)

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study
por: Llanos, Jean-Pierre, et al.
Publicado: (2019)

Severe Pediatric Asthma Therapy: Mepolizumab
por: Ullmann, Nicola, et al.
Publicado: (2022)

Does NSAID exacerbated respiratory disease (N-ERD) accompanying severe asthma affect biological treatment response? Efficacy of omalizumab and mepolizumab in N-ERD
por: Tepetam, Fatma Merve, et al.
Publicado: (2023)

Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review
por: Cao, Peng, et al.
Publicado: (2022)

Case report: Severe chronic spontaneous urticaria successfully treated with omalizumab and dupilumab
por: Puxkandl, Viktoria, et al.
Publicado: (2023)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

May mepolizumab used in asthma correct subfertility?
por: Ozden, Guzin, et al.
Publicado: (2021)

Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty: Two triple-switch case reports
por: Lombardi, Carlo, et al.
Publicado: (2019)

Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008)

Omalizumab treatment in brittle asthma
por: Skiepko, Roman, et al.
Publicado: (2014)

Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: A case report
por: Kai, Yoshiro, et al.
Publicado: (2022)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Characteristics of new adult users of mepolizumab with asthma in the USA
por: Wu, Ann Chen, et al.
Publicado: (2021)

Daily Physical Activity in Asthma and the Effect of Mepolizumab Therapy
por: Panagiotou, Marios, et al.
Publicado: (2022)

Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2020)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Complete response to dupilumab in a patient with chronic spontaneous urticaria who did not tolerate omalizumab
por: Zhu, Changhua, et al.
Publicado: (2022)

The Role of Dupilumab in Severe Asthma
por: Ricciardolo, Fabio Luigi Massimo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4v6l2bc2a95bs63gd1erj8mr3t